Sodium-glucose cotransporter 2 (SGLT-2) inhibitors (gliflozins)represent the most recently approved class of oral antidiabetic drugs.SGLT-2 overexpression in diabetic patients contributes significantlyto hyperglycemia and related complications. This evidence concerns the gene SLC5A2 and Hyperglycemia.